Drug interaction risk is not uniform across clinical settings. The interactions that cause the most patient harm in any given context are determined by which drugs are most commonly prescribed, which patient populations are most prevalent, and which disease combinations drive the highest polypharmacy burden. In the Caribbean, those factors produce a specific and identifiable pattern of high-risk interactions that every prescribing clinician in the region should have front of mind.
The interactions reviewed here are not necessarily rare or poorly documented — many are well-established in the pharmacological literature. What makes them particularly relevant to Caribbean practice is the frequency with which the drug combinations involved appear in the region's prescribing pattern, driven by the high prevalence of hypertension, type 2 diabetes, atrial fibrillation, and heart failure across the population.
Anticoagulation Interactions
Warfarin remains the most widely used oral anticoagulant across much of the Caribbean, where access to direct oral anticoagulants remains limited by cost and availability. Its narrow therapeutic index and extensive interaction profile make warfarin-related interactions consistently among the highest-risk in Caribbean practice.
Amiodarone inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism. This produces a significant and prolonged elevation in warfarin plasma concentration, dramatically increasing bleeding risk. The effect is delayed — it may not become apparent for one to two weeks after amiodarone initiation — and persists for weeks to months after amiodarone discontinuation due to its extremely long half-life.
Caribbean relevance: Atrial fibrillation prevalence is high in the Caribbean. Amiodarone is widely used for rhythm control. Warfarin is the available anticoagulant for stroke prevention. This combination is common and requires close INR monitoring with warfarin dose reduction when amiodarone is initiated.
NSAIDs inhibit platelet aggregation and can cause gastrointestinal mucosal damage, both of which significantly increase bleeding risk in a patient already anticoagulated with warfarin. Some NSAIDs also displace warfarin from plasma protein binding sites, transiently increasing free warfarin concentration.
Caribbean relevance: NSAIDs are widely available over the counter across the Caribbean and frequently used for musculoskeletal pain without clinical review. Patients on warfarin self-medicating with ibuprofen or diclofenac represent a significant unmonitored risk.
Fluconazole is a potent inhibitor of CYP2C9 and CYP3A4. Even a short course — the single-dose 150mg regimen commonly used for vaginal candidiasis — produces a clinically significant elevation in warfarin effect. INR can rise substantially within 24 to 48 hours of fluconazole administration.
Caribbean relevance: Fungal infections are common in a tropical climate. Fluconazole is widely prescribed and available OTC in many territories. The single-dose regimen gives a false impression of minimal systemic exposure — the warfarin interaction is real and can be severe.
Cardiovascular and Metabolic Interactions
ACE inhibitors reduce aldosterone production, decreasing renal potassium excretion. When combined with a potassium-sparing diuretic such as spironolactone or amiloride, or with potassium supplementation, the additive effect on potassium retention can produce dangerous hyperkalaemia — particularly in patients with impaired renal function, which is common in the Caribbean diabetic hypertensive population.
Caribbean relevance: The combination of an ACE inhibitor for hypertension or diabetic nephroprotection with spironolactone for heart failure or resistant hypertension is clinically appropriate in selected patients but requires careful electrolyte monitoring. Renal impairment — common in the target population — amplifies the risk significantly.
Iodinated contrast agents used in radiological investigations can cause acute kidney injury. In the context of renal impairment, metformin accumulates and the risk of metformin-associated lactic acidosis increases significantly. Current guidelines recommend withholding metformin at the time of contrast administration and for 48 hours post-procedure, resuming only after renal function has been confirmed stable.
Caribbean relevance: Type 2 diabetes is highly prevalent across the Caribbean. Metformin is first-line therapy. Radiological investigations requiring contrast are common in the management of cardiovascular and renal complications. This interaction is frequently missed in the procedural pathway.
Amiodarone inhibits CYP3A4 and CYP2C8, pathways involved in the metabolism of several statins. Simvastatin is particularly affected — the combination carries an elevated risk of myopathy and rhabdomyolysis. Atorvastatin is less affected but monitoring is warranted. Rosuvastatin, which has minimal CYP metabolism, is the preferred statin in patients requiring amiodarone.
Caribbean relevance: Dyslipidaemia coexisting with atrial fibrillation managed on amiodarone is a common clinical scenario. Statin choice in this context matters — simvastatin should be avoided or used at the lowest possible dose.
Trimethoprim blocks renal tubular potassium secretion through a mechanism similar to potassium-sparing diuretics. In combination with an ACE inhibitor or ARB — both of which reduce aldosterone-driven potassium excretion — the additive effect can produce clinically significant hyperkalaemia, particularly in older patients and those with renal impairment.
Caribbean relevance: Urinary tract infections are common in the Caribbean diabetic population, which also has a high prevalence of ACE inhibitor or ARB use for nephroprotection. Co-trimoxazole is widely prescribed. This combination appears frequently and the hyperkalaemia risk is underappreciated.
Why These Interactions Recur
The Caribbean Prescribing Context
- High NCD burden drives high polypharmacy — patients with hypertension, diabetes, and dyslipidaemia are routinely on five or more medications. Each additional drug increases the interaction surface area.
- Multi-prescriber environments — patients often see a general practitioner, a specialist, and may access OTC medications independently. No single prescriber has visibility of the complete medication list without active reconciliation.
- OTC availability of interacting drugs — NSAIDs, fluconazole, and other significant interactors are available without prescription across many Caribbean territories. Patient self-medication is not always disclosed at clinical encounters.
- Limited laboratory monitoring infrastructure in some settings — interactions that require INR or electrolyte monitoring to manage safely are more difficult to manage where laboratory access is inconsistent or delayed.
- Warfarin as the dominant anticoagulant — the cost and availability barriers to DOACs mean warfarin remains prevalent, keeping its extensive interaction profile clinically relevant in a way it is not in markets where DOAC access is routine.
ElesRx flags all of the interactions reviewed in this article. The pharmacoai database covers the drug combinations most relevant to Caribbean prescribing practice, with severity classification and mechanism detail included with each alert. For clinicians managing complex NCD patients across the Caribbean, checking a new prescription against the patient's existing regimen takes less than a minute. The interactions described here are preventable.
Check Interactions in Your Patient's Regimen
ElesRx — clinical decision support built for Caribbean prescribing practice.
Access ElesRx